Publications by authors named "R Rae"
Unlabelled: The locus coeruleus (LC) is the primary source of noradrenaline (NA) in brain and its activity is essential for learning, memory, stress, arousal, and mood. LC-NA neuron activity varies over the sleep-wake cycle, with higher activity during wakefulness, correlating with increased CSF NA levels. Whether spontaneous and burst firing of LC-NA neurons during active and inactive periods is controlled by mechanisms independent of wakefulness and natural sleep, is currently unknown.
View Article and Find Full Text PDFThe large pine weevil ( L.) is a major pest in European and Asian coniferous forests, particularly in managed plantations where clear-felling practices create ideal conditions for its population growth. Traditional management practices involving synthetic insecticides have limited efficacy in terms of reducing pest populations and pose environmental risks.
View Article and Find Full Text PDFFinancial assistance for snakebite envenoming by OECD nations.
Trans R Soc Trop Med Hyg
January 2025
Background: The World Health Organization re-established snakebite as a neglected tropical disease in 2017. An overview is provided on snakebite financial assistance in relation to the policy landscape change.
Methods: The Organisation for Economic Co-operation and Development Creditor Reporting System database was searched and 184 results obtained from 1999 to 2022 underwent simple Excel analysis.
T cell bispecific antibodies (TCBs) are a promising new class of therapeutics for relapsed/refractory multiple myeloma. A frequently observed, yet incompletely understood effect of this treatment is the transient reduction of circulating T cell counts, also known as T cell margination (TCM). After administration of the GPRC5D-targeting TCB forimtamig (RG6234), TCM occurred in patients and correlated with cytokine release and soluble B cell maturation antigen decrease.
View Article and Find Full Text PDFArticle Synopsis
- Multiple myeloma (MM) is still an incurable cancer despite available therapies, with T-cell bispecific antibodies (TCBs) targeting BCMA and GPRC5D showing promise but facing issues like resistance and relapse due to antigen loss.
- Forimtamig is a novel GPRC5D-targeting TCB that works more effectively than traditional formats by forming stable immunological connections, leading to better tumor cell destruction and T cell activation in preclinical studies.
- Current research is exploring forimtamig in clinical trials for relapsed and refractory MM patients, both alone and alongside traditional care and new therapies, to enhance treatment outcomes and prevent relapses.